TECH — BIO-TECHNE CORPORATION

Bio-Techne's R&D Systems brand is the dominant supplier of research-grade cytokines, proteins, and antibodies for the global life sciences industry — a citation-driven franchise with 67% gross margins built over four decades by the simple mechanism of scientists building experimental protocols around R&D Systems reagents and never switching. The company is navigating a convergence of temporary headwinds — biotech funding softness, NIH funding cuts, and a specific cell therapy customer order timing disruption — that have pushed Protein Sciences margins to multi-year lows and organic growth to near-zero, while the stock trades at approximately 21 times adjusted operating income against a peer set at 15 to 17 times. Interesting but requires a specific catalyst to be actionable: evidence in the second half of fiscal 2026 that cell therapy revenues are recovering and Protein Sciences margins are returning toward 43%, confirming the core franchise is intact and the current compression is cycle rather than structure.

---

The life sciences tools sector spent the better part of four years in retreat. From the extraordinary peak of 2021 — when COVID-era demand had inflated purchasing across biopharma, government-funded research spending was expanding, and growth rates for reagent suppliers prompted market capitalizations that in retrospect made no sense — the sector corrected sharply. Inventory destocking hit reagent companies starting in late 2022 as biopharma customers worked down pandemic-era excess. Biotech funding contracted as rising rates made capital scarcer, and the number of early-stage companies able to sustain experimental spending declined measurably. The normalization took longer and cut deeper than most expected.

The research landscape in early 2026 is messier still. Biotech funding has partially recovered — venture capital into life sciences reached meaningful levels again in 2024 and 2025 — but a new headwind has emerged. Approximately $3.8 billion in NIH grants were terminated through mid-2025, representing direct hits to the academic laboratory customers who purchase reagents, antibodies, and protein analysis instruments. Top research universities are absorbing funding losses in the hundreds of millions annually. Bio-Techne's academic and government-funded customer segment reported low single-digit declines in the most recent quarters. Unlike the inventory destocking cycle, this headwind moves on political timelines that are harder to predict than demand cycles.

Into this environment, Bio-Techne Corporation sits at a peculiar intersection. Its core franchise is one of the genuine crown jewels of the life sciences tools sector: R&D Systems, the dominant supplier of research-grade cytokines and proteins whose products appear in the protocols of essentially every active biology laboratory studying cell signaling, immune function, or cancer biology. Its newer businesses — spatial biology via the COMET platform, GMP-grade proteins for cell and gene therapy manufacturing — are earlier-stage and more volatile. And its shares have declined from a 2021 peak of approximately $480 to roughly $52 today: a drop of nearly 90%, representing the combined effect of sector re-rating, a year of near-zero organic growth, and an acquisition strategy that left behind a balance sheet heavy with goodwill and at least one clear capital allocation failure.

The life sciences research tools sector is not uniform in structure. The broad category — analytical instruments, laboratory consumables, and research-grade biological reagents — represents approximately $150 to $200 billion in global annual spending, growing at 7 to 10% per year. Within that category, the most defensible subsegment is research-grade biological reagents: the cytokines, growth factors, recombinant proteins, and validated antibodies that scientists use to conduct specific experiments. These are not commodity chemicals. A researcher studying interleukin-17 in inflammatory disease cannot substitute one supplier's cytokine for another's — the reagent cited in published protocols, validated by other researchers in the field, referenced in the methods sections of a thousand papers, is the reagent the next researcher buys. This citation-based lock-in is the structural mechanism that makes research-grade biological reagents a genuinely defensive product category.

The structural forces that shape competition in this subsegment favor the incumbent with the largest published citation footprint, the broadest validated product portfolio, and the deepest manufacturing expertise. Entry is not trivially easy: producing bioactive recombinant proteins that perform consistently across assay conditions requires decades of process knowledge. Validation requires time and customer adoption. The citation network builds slowly and compounds — once R&D Systems cytokines appear in a hundred papers on a specific pathway, every researcher who wants their work reproducible against that literature will use R&D Systems products. The research-grade proteins market was approximately $936 million globally in 2024, growing toward $1.75 billion by 2030 at an 11.5% compounded rate. The broader research antibodies and reagents market represents approximately $20 billion. Generalist competitors like Thermo Fisher Scientific and Danaher compete on scale and cross-sell, but neither has displaced R&D Systems from its position as the reference standard for research-grade proteins and cytokines in the specific high-value subcategories it dominates.

Bio-Techne Corporation, through its R&D Systems brand, manufactures more than 5,000 recombinant proteins, more than 400,000 antibody products, and a growing portfolio of GMP-grade cytokines and growth factors for clinical-stage cell and gene therapy applications. The business operates across two reported segments: Protein Sciences, which contributes approximately 72 to 75% of total revenue and includes R&D Systems, cell therapy tools, and protein analysis instruments; and Diagnostics and Spatial Biology, which contributes 25 to 28% and encompasses the COMET spatial multiomics platform, advanced diagnostics kits, and the recently divested Exosome Diagnostics business. The Protein Sciences segment is the crown jewel: a mature, high-margin franchise with 44 to 46% adjusted operating margins in periods of normal demand. The Diagnostics and Spatial Biology segment is earlier-stage, more volatile, and carries substantially lower margins.

The GMP-grade protein opportunity is a natural adjacency that deserves specific attention. Bio-Techne operates a dedicated Good Manufacturing Practice facility in St. Paul, Minnesota producing animal-free cytokines and growth factors for cell therapy manufacturing — the same proteins used in research, but manufactured to the quality standards required for clinical production. More than 1,300 cell and gene therapy programs are currently in active clinical trials globally; each requires GMP-grade cytokines for ex-vivo cell expansion. Researchers who validated protocols using R&D Systems research-grade cytokines are the natural buyers of R&D Systems GMP-grade equivalents when those protocols transition to clinical manufacturing. The brand advantage transfers across the research-to-clinical boundary without requiring a new competitive win.

The competitive moat is most clearly visible in the margin comparison. Bio-Techne's Protein Sciences segment generates adjusted operating margins of 44 to 46% in periods of normal demand. This is not a favorable-conditions artifact — it reflects the pricing power of a supplier whose products are protocol-embedded and non-substitutable for the specific use case. The gap versus generalist competitors is structural, not cyclical.

Company / Segment	Gross Margin	Adjusted Operating Margin	Revenue
Bio-Techne (Protein Sciences)	~74%	~44%	~$881M
Bio-Techne (consolidated)	67%	31.6%	$1,227M
Thermo Fisher Scientific	41%	~18%	$44.6B
Danaher Corporation	61%	~18%	$23.5B

The 26-percentage-point gross margin advantage over Thermo Fisher is not a temporary condition — it reflects the fundamental difference between a specialist manufacturer of proprietary research-grade biologics and a diversified life sciences conglomerate. Bio-Techne's 67% gross margin is achieved because R&D Systems produces reagents whose pricing reflects their scientific specificity rather than their raw material cost. R&D Systems holds 33 products in the top 100 most-cited global growth factors. A cytokine used in five thousand published experiments cannot be commoditized regardless of what a competitor charges for a structurally similar protein.

Financially, the picture is more complex than the margin quality suggests. Fiscal 2025 revenue of $1,227 million grew 5% organically from fiscal 2024's $1,168 million, which itself had grown only 1% organically. The multi-year revenue growth rate across three fiscal years has been approximately 2 to 3% per year — materially below the rates the 2021 market priced. Fiscal 2025 GAAP earnings per share were $0.46, down 56% from $1.05 in fiscal 2024. The GAAP decline is genuinely distorted by two large non-recurring items: an $83.1 million impairment on the Exosome Diagnostics business (which was subsequently sold for $5 million in stock — a near-total destruction of the original acquisition cost) and a $39 million non-recurring litigation charge. Adjusted earnings per share, excluding these items along with intangible amortization and stock-based compensation, were $1.92 in fiscal 2025, representing 8% growth from fiscal 2024's $1.77.

The GAAP-to-adjusted reconciliation merits scrutiny. The persistent annual adjustments beyond one-time items include approximately $80 million in amortization of intangible assets from the company's acquisition history and approximately $50 million in stock-based compensation. The amortization is a real cost: it is the accounting recognition of real cash spent on 19 acquisitions over eleven years. The Exosome Diagnostics story illustrates the problem in concentrated form — $250 million spent in 2018, an $83.1 million impairment recorded in fiscal 2025, and a sale for $5 million shortly thereafter. That is a complete destruction of invested capital. The adjusted EPS of $1.92 overstates sustainable normalized earnings power by excluding amortization of a real acquisition expenditure, even if that cash has already been deployed. The honest earnings figure sits somewhere between the GAAP $0.46 and the adjusted $1.92 — closer to $1.50 to $1.60 when adding back the large one-time items (impairment, litigation) but retaining the amortization and SBC charges as real costs.

New CEO Kim Kelderman, appointed in February 2024, represents a deliberate strategic shift. Where his predecessor Chuck Kummeth executed 19 acquisitions in 11 years and built revenue from $311 million to over $1 billion, Kelderman's stated orientation is operational integration — getting more out of what was acquired rather than layering in more. His background includes operational roles at Becton Dickinson and Thermo Fisher. In May 2025, the Board authorized a new $500 million share repurchase program, the largest in the company's history, signaling that capital will be directed toward per-share value rather than balance sheet expansion. Quarterly dividends continue. The strategic posture is correct: the company does not need another acquisition at this stage; it needs to demonstrate that what it owns generates consistent returns. Insider ownership at approximately 1.1% of the company is lower than one would prefer for a management team asking shareholders to be patient through a recovery.

The growth runway table is where the trajectory becomes visible and the nature of the current headwinds becomes testable.

Fiscal Year	Revenue	Organic Growth	Protein Sciences Adj. Op. Margin	D&SB Adj. Op. Margin	Adjusted EPS
FY2023 (ended Jun 2023)	$1,138M	5%	44.2%	14.7%	$1.99
FY2024 (ended Jun 2024)	$1,168M	1%	43.0%	12.5%	$1.77
FY2025 (ended Jun 2025)	$1,227M	5%	~44%	~8%	$1.92
FY2026E (H1 actual + H2 guided)	~$1,245M	~1–2%	~39%	~11%	~$1.73

Three things are visible simultaneously in this table. First, organic revenue growth has been uneven and low — 5%, 1%, 5%, and approximately 1 to 2% — reflecting a business without the structural demand tailwinds that make consistent compounding easy. Second, and most importantly, the Protein Sciences adjusted operating margin has compressed from 44.2% in fiscal 2023 to approximately 39% in the first half of fiscal 2026. This compression is the heart of the current investment question. Management has attributed the decline primarily to a specific, identifiable cause: two of Bio-Techne's largest cell therapy customers received FDA Fast Track designations in calendar 2025, accelerating their clinical timelines and deferring their bulk GMP protein orders as manufacturing lead times shifted. Excluding these two customers, GMP reagent revenues grew approximately 30% organically in the first half of fiscal 2026 — demonstrating that the underlying cell therapy demand picture is intact. The headwind was 200 basis points in Q1 and 400 basis points in Q2, and management guided for a 300 basis point improvement beginning in Q3. Third, the Diagnostics and Spatial Biology segment margin improved materially after the Exosome Diagnostics divestiture — from approximately 8% in fiscal 2025 to approximately 11% in the first half of fiscal 2026 — an improvement whose direction matters even if the absolute level remains far below the Protein Sciences benchmark.

The structural driver for the earnings recovery is the resolution of the cell therapy timing headwind alongside the ongoing growth in the broader cell and gene therapy tools market. More than 1,300 cell therapy programs are in active global clinical trials. Each program that advances from Phase 1 to Phase 2 requires proportionally larger volumes of GMP-grade cytokines. Bio-Techne's competitive position in this transition is the R&D Systems brand advantage applied at the research level — researchers who standardized on R&D Systems cytokines at the bench become Bio-Techne GMP customers as their programs advance, without requiring Bio-Techne to win a new competitive evaluation. Excluding the two timing-affected customers, the GMP reagent business grew 30% organically. When those customers resume normal ordering patterns in the second half of fiscal 2026 and into fiscal 2027, the headwind reverses without requiring any new demand creation.

The spatial biology platform adds optionality that is not yet in the earnings base. COMET bookings grew nearly 40% year-over-year in the second quarter of fiscal 2026, the second consecutive quarter of strong acceleration. The platform's differentiation — fully automated hyperplex spatial multiomics combining protein and RNA detection — addresses a genuine bottleneck in biopharma drug discovery and tissue analysis. The spatial biology market was approximately $1 billion in 2025, growing at a 10 to 19% compounded annual rate depending on scope. At $350,000 per instrument and an annual pull-through target of $90,000 in consumables — against the current approximately $45,000 achieved — COMET has the potential to contribute meaningfully to segment margins as the installed base grows. Bio-Techne has captured an early position in a market that is still in its instrument-placement phase; the recurring consumable revenue compounds as placements accumulate.

Bio-Techne's Protein Sciences segment generates approximately $881 million in annual revenue across research-grade proteins, antibodies, immunoassay instruments, and GMP biologics. Within the research-grade proteins and cytokines subcategory specifically — where R&D Systems holds citation dominance across 33 of the top 100 most-cited global growth factors — the company's market share in its specific product lines is substantial, likely 40 to 60% of that subcategory's spending. Across the broader $20 billion research antibodies and reagents market, Bio-Techne's current penetration is approximately 4 to 5% — implying a significant runway if the R&D Systems brand advantage extends to antibody categories where its citation position is not yet dominant. The company has captured its core cytokine and growth factor market deeply; the growth opportunity in antibodies, spatial biology, and cell therapy biologics represents a TAM that is multiples of the current revenue base.

At $52.27 per share and approximately 155 million diluted shares, Bio-Techne carries a market capitalization of approximately $8.1 billion. Against cash of $173 million and long-term debt of $260 million as of December 2025, the enterprise value is approximately $8.2 billion. This translates to approximately 21 times adjusted operating income of approximately $388 million, approximately 27 times trailing adjusted earnings per share of $1.92, and approximately 30 times last twelve months free cash flow. Against the life sciences tools peer set — Waters Corporation at approximately 15 times EV/adjusted EBITDA, Thermo Fisher at approximately 17 times, Mettler-Toledo at approximately 21 times — Bio-Techne trades at the upper end of the peer range. The premium is partially justified by Bio-Techne's superior gross margins and its citation franchise; it is partially unjustified by modest organic growth and adjusted EPS that has been flat to declining across three fiscal years despite revenue growing from $1,138 million to approximately $1,245 million estimated.

The core Protein Sciences business, evaluated alone, is a genuinely high-quality capital allocator. Generating approximately $388 million in annual adjusted operating income on net tangible assets — the equity base stripped of $1.2 to $1.5 billion in goodwill and acquired intangibles from 19 acquisitions — implies returns on unleveraged net tangible capital in the range of 65 to 90%. These are the returns of a premium compounder: a business where the marginal dollar of investment generates outsized returns because the product is non-substitutable and pricing is determined by protocol embeddedness rather than competitive bidding. The problem is that this high-quality core is combined with a lower-quality Diagnostics and Spatial Biology segment, a goodwill-burdened balance sheet from a partly successful acquisition history, and three consecutive years of flat-to-declining adjusted earnings power despite modest revenue growth — the precise combination that makes it difficult to establish what normalized earnings actually are.

The verdict is: interesting but requires a specific catalyst to be actionable. The R&D Systems citation franchise is real and durable. The cell therapy adjacency is a credible source of non-dilutive growth from an installed research base. The new CEO's operational orientation and the $500 million buyback authorization signal the right capital allocation instincts. But at 21 times adjusted operating income and 27 to 30 times adjusted earnings during a period of near-zero organic growth and margin compression, the market is already pricing in partial recovery. The catalyst is specific: Q3 and Q4 fiscal 2026 results showing Protein Sciences adjusted operating margins recovering from 39% toward 43% as cell therapy order timing normalizes, total organic growth accelerating to 4 to 6%, and COMET bookings sustaining their trajectory. Those data points will appear or not within two reporting periods.

The most credible bear objection is that the margin compression is structural, not cyclical: that the decade-long decline in adjusted operating margins — from approximately 38% in fiscal 2022 to 31.6% in fiscal 2025 — reflects a business permanently losing pricing power as Thermo Fisher and Danaher build their research-grade protein and antibody portfolios. The Danaher acquisition of Abcam and Thermo Fisher's continued investment in protein expression tools have given both companies meaningfully stronger positions in research-grade reagents than they held five years ago. This argument cannot be dismissed. The answer is that gross margins have remained at 67% through this period — pricing power, which would show first in gross margins, is intact. The operating margin erosion reflects cost inflation and mix (the lower-margin D&SB segment growing as a share of revenue), not price erosion. The gross margin is the test of moat quality; it is not breaking.

What would need to change to alter the verdict: a decline from $52 to approximately $40 to $45 per share — implying 15 to 17 times adjusted operating income, in line with the life sciences tools peer median — would offer a meaningful margin of safety and make the thesis compelling regardless of the specific timing of the recovery. At that price, the investor is paying the peer multiple for a business with above-peer gross margins, a citation franchise that peers cannot replicate, and the cell therapy GMP adjacency as free optionality. Alternatively, two consecutive quarters of Protein Sciences margin recovery toward 43% alongside 5% organic growth would confirm the current compression is timing-driven, at which point the current price would prove to have been the right entry.

R&D Systems has been building its citation advantage since it released TGF-beta 1 commercially in 1985. Four decades of protocol validation is not replicable in a product development cycle. The graduate students learning their craft on R&D Systems cytokines today will specify R&D Systems in lab orders for the next thirty years. At $52, the market is charging a modest premium for that franchise against a backdrop where near-term earnings are temporarily compressed. That premium is not a discount — but the business at the right price, when the cell therapy headwind has visibly turned, is worth owning for the decade that follows.